Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
In: Clinical and Applied Thrombosis/Hemostasis, Jg. 27 (2021-11-01)
Online
unknown
Zugriff:
A variety of antithrombotic drugs are used during percutaneous coronary interventions (PCIs). We aimed to investigate the practicability of the use of bivalirudin and GPIs in patients receiving PCI. We searched 7 of 629 relevant records from PubMed, the Cochrane Library, EMBASE, and Web of Science for randomised controlled trials. There were no significant differences in the rates of major adverse cardiac events (MACE) between bivalirudin plus GPI and heparin (all P > .05). Bivalirudin plus planned GPI was similar to bivalirudin monotherapy in terms of the risk of MACE (risk ratio [RR] = 1.07; 95% confidence interval [CI] = .91 − 1.27; P = .55). Bivalirudin plus provisional GPI was associated with lower bleeding risk (RR = .57; 95% CI = .47 − .69; P
Titel: |
Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
|
---|---|
Autor/in / Beteiligte Person: | Lv, Dongqing ; Liu, Caihong ; Jia, Yongping ; Li, Senjie |
Link: | |
Zeitschrift: | Clinical and Applied Thrombosis/Hemostasis, Jg. 27 (2021-11-01) |
Veröffentlichung: | SAGE Publishing, 2021 |
Medientyp: | unknown |
ISSN: | 1938-2723 (print) |
Schlagwort: |
|
Sonstiges: |
|